Marinus Pharma (MRNS) Announces Ganaxolone Orphan Epilepsy Program Updates Including Planned Clinical Program in TSC

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. DFTX
10. NKE

Go back to Marinus Pharma (MRNS) Announces Ganaxolone Orphan Epilepsy Program Updates Including Planned Clinical Program in TSC

Marinus Announces Ganaxolone Orphan Epilepsy Program Updates Including Planned Clinical Program in Tuberous Sclerosis Complex

December 9, 2019 6:30 AM EST

Initiation of Phase 2 trial evaluating ganaxolone in tuberous sclerosis complex planned for 1H 2020

European Medicines Agency Orphan Drug Designation granted for ganaxolone for the treatment of CDKL5 deficiency disorder

CDKL5 deficiency disorder pivotal Phase 3 trial on-track for data Q3 2020 with strong ongoing enrollment

RADNOR, Pa., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (Marinus or... More